Get the Daily Brief
Latest Biotech News
Guardant and Zephyr tie up: AI meets circulating tumor genomics
Guardant Health entered a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its genomic testing platform with Zephyr’s analytics to accelerate biomarker...
USP releases GLP‑1 standards: Quality push amid fraud and shortages
The U.S. Pharmacopeia released reference standards and analytical reference materials (ARMs) to help manufacturers test GLP‑1 peptide therapeutics for product‑ and process‑related impurities. USP...
NHS vets 15‑minute blood test for sepsis screening in children
Three pediatric emergency departments in England are trialing Memed BV’s rapid blood test, which produces results in as little as 15 minutes to differentiate bacterial from viral infections. The...
Novartis buys Avidity for $12B — secures three late‑stage RNA neuromuscular drugs
Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, adding three antibody‑oligonucleotide conjugate (AOC) programs aimed at Duchenne muscular dystrophy (DMD), myotonic...
Intellia halts Phase 3 CRISPR dosing — liver safety probe underway
Intellia Therapeutics paused enrollment and dosing in two late‑stage trials of its CRISPR therapy nex‑z after a trial volunteer was hospitalized with severe liver injury. The company stopped...
Zenas’ obexelimab nearly eradicates new MS lesions — mid‑stage readout
Zenas Biopharma reported a mid‑stage (MoonStone) trial in relapsing multiple sclerosis where obexelimab, a bifunctional monoclonal antibody, produced a roughly 95% reduction in new...
BridgeBio posts positive Phase 3—prepares FDA meeting for rare muscular dystrophy filing
BridgeBio announced a positive interim Phase 3 readout for BBP‑418 (ribitol) in limb‑girdle muscular dystrophy type 2I/R9, meeting prespecified thresholds and producing clinically meaningful...
Hemab raises $157M to build 'ultimate coagulation disorders' company
Hemab Therapeutics closed a $157 million financing to advance a portfolio of coagulation‑disorder programs, including a sutacimig pivotal trial planned for Glanzmann thrombasthenia and an...
Real‑time nanopore metagenomics: MARTi enables in‑field pathogen surveillance
Researchers at the Earlham Institute released MARTi, an open‑source software suite that enables real‑time analysis and visualization of nanopore metagenomic data. MARTi runs on standard laptops or...
USP issues GLP‑1 quality standards as nonresponse and counterfeits spotlight market risks
The U.S. Pharmacopeia released reference standards and analytical reference materials to help manufacturers test GLP‑1 peptide therapeutics for product‑ and process‑related impurities amid surging...
New Streptomyces intermediate yields potent antibiotic lead against MRSA and VRE
Researchers identified a previously untested biosynthetic intermediate—pre‑methylenomycin C lactone—from Streptomyces coelicolor that shows markedly higher activity against Gram‑positive pathogens...
Proteomics International posts sevenfold Q3 revenue after UWA collaboration
Australian diagnostics firm Proteomics International reported A$1.9 million in Q3 2025 revenue, a more than sevenfold increase year‑over‑year driven by a nonrecurring A$1.7 million collaboration...
AI meets multimodal biomolecules and biomarkers — BoltzGen and Guardant‑Zephyr tie ups
Two AI‑driven advances signaled fast adoption of machine learning across discovery and translational pipelines. An MIT team released BoltzGen, an open‑licensed generative model that designs...
Novartis shells out $12B for Avidity—gains three late‑stage RNA drugs
Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, adding three late‑stage antibody‑oligonucleotide conjugate (AOC) programs targeted at neuromuscular diseases. The deal...
Intellia halts nex‑z Phase III dosing after serious liver event
Intellia Therapeutics paused enrollment and dosing in two phase III trials of its CRISPR candidate nex‑z (nexiguran ziclumeran) after a study volunteer was hospitalized with severe liver toxicity....
BridgeBio posts pivotal win — pivots filing plans for rare muscular dystrophy
BridgeBio reported positive Phase III interim results for BBP‑418 in limb‑girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), prompting company plans to meet the FDA to discuss regulatory filing...
Zenas’ obexelimab wipes out MRI lesions — midstage multiple sclerosis win
Zenas Biopharma reported that obexelimab produced a 95% reduction in new gadolinium‑enhancing MRI lesions at Weeks 8–12 in its midstage MoonStone relapsing multiple sclerosis study. The...
Hemab raises $157M to tackle underserved coagulation disorders
Hemab Therapeutics closed a $157 million financing to advance a pipeline focused on rare bleeding disorders, funding pivotal plans and clinical expansion. The Series C round was led by Sofinnova...
USP issues GLP‑1 standards as patient response and counterfeit risks rise
The U.S. Pharmacopeia released reference standards and analytical reference materials to help manufacturers and labs ensure purity and detect impurities in GLP‑1 peptide therapeutics amid surging...
Health Canada clears lecanemab for early Alzheimer’s — conditional authorization
Health Canada issued a Notice of Compliance with Conditions for Eisai and Biogen’s lecanemab (LEQEMBI) to treat adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease...